Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CETP | P11597 | 6/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SOD1 | P00441 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25094106 | 0.89 | KIF11 (0.50) | KIF11ACHEKCNH2TRPV1SCN10A | |
| SCHEMBL12163571 | 0.88 | CYP3A4 (0.45) | KIF11CYP3A4CYP2C9CYP2C19CETP | |
| SCHEMBL4968089 | 0.85 | KIF11 (0.50) | KIF11CYP3A4CYP2C9CETPKCNH2 | |
| SCHEMBL13439848 | 0.84 | MAOB (0.54) | CETPSOD1HTTL3MBTL1 | |
| SCHEMBL11527555 | 0.83 | KIF11 (0.51) | KIF11CETPL3MBTL1 | |
| SCHEMBL13649193 | 0.83 | CYP3A4 (0.47) | KIF11CYP3A4CYP2C9CYP2C19CETP | |
| SCHEMBL12247693 | 0.83 | CETP (0.54) | CYP3A4CYP2C9CYP2C19CETPACHE | |
| SCHEMBL17552755 | 0.83 | KIF11 (0.49) | KIF11CYP2C9CETPKCNH2SCN10A | |
| SCHEMBL21695566 | 0.82 | CYP3A4 (0.44) | KIF11CYP3A4CYP2C9CYP2C19CETP | |
| SCHEMBL13439845 | 0.81 | NR4A1 (0.51) | CETPSOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20230382902-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382902-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-30 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230355617-A1 | SMALL MOLECULE INHIBITORS OF LEMUR TYROSINE KINASE 3 | THE UNIVERSITY OF SUSSEX (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230339871-A1 | COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | METREA BIOSCIENCES INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-11786500-B2 | Glutaminase inhibitor therapy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786500-B2 | Glutaminase inhibitor therapy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786528-B2 | Pyrazolopyrimidine compounds as adenosine receptor antagonists | EXSCIENTIA LTD. (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-7217712-B2 | 4-Substituted-5-cyano-1H-pyrimidin-6-(thi)ones as GSK-3 inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-15 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ALZHEIMER'S INSTITUTE OF AMERICA, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | KIF11 3334/4885CYP3A4 819/4885CYP2C9 2239/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | KIF11 4469/4885CYP3A4 537/4885CYP2C9 769/4885 |
| US-20070066599-A1 | New compounds | SULT2A1, GPR119, STS | KIF11 4500/4885CYP3A4 1195/4885CYP2C9 458/4885 |
| US-11786528-B2 | Pyrazolopyrimidine compounds as adenosine receptor antagonists | ADORA1, ADORA3, ADORA2A | KIF11 3584/4885CYP3A4 135/4885CYP2C9 131/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | KIF11 4469/4885CYP3A4 537/4885CYP2C9 769/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | KIF11 4505/4885CYP3A4 976/4885CYP2C9 223/4885 |
| US-20230382902-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LIPC | KIF11 3440/4885CYP3A4 1924/4885CYP2C9 1213/4885 |
| US-20230355617-A1 | SMALL MOLECULE INHIBITORS OF LEMUR TYROSINE KINASE 3 | LMTK3, LMTK2, LIMK1 | KIF11 2168/4885CYP3A4 4443/4885CYP2C9 4163/4885 |
| US-11786500-B2 | Glutaminase inhibitor therapy | ASNS, GLS, GLS2 | KIF11 4629/4885CYP3A4 3555/4885CYP2C9 3215/4885 |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | KIF11 4814/4885CYP3A4 3885/4885CYP2C9 4440/4885 |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LPAR1 | KIF11 2948/4885CYP3A4 856/4885CYP2C9 1089/4885 |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRM1 | KIF11 2678/4885CYP3A4 1798/4885CYP2C9 1313/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | KIF11 4505/4885CYP3A4 976/4885CYP2C9 223/4885 |
| US-20230339871-A1 | COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | HSD17B1, HSD17B13, HSD17B11 | KIF11 3161/4885CYP3A4 394/4885CYP2C9 793/4885 |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | KIF11 3425/4885CYP3A4 762/4885CYP2C9 976/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KIF11 2411/4885CYP3A4 1414/4885CYP2C9 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.